Organization and Summary of Significant Accounting Policies |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Accounting Policies [Abstract] | |
| Organization and Summary of Significant Accounting Policies |
Note 1 – Organization and Summary of Significant Accounting Policies
Organization
Processa Pharmaceuticals, Inc. (the “Company,” “we,” “us,” and “our”) is a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases. On July 28, 2026, we acquired Vidya Therapeutics, Inc. (“Vidya”), a private company pursuant to the terms of an Agreement and Plan of Merger, dated as of July 28, 2026 (the “Merger Agreement” and the transaction consummated pursuant to the Merger Agreement, the “Vidya Acquisition”) by and among the Company, Vidya, and certain merger subsidiaries that were party to the Merger Agreement.
The Vidya Acquisition brought into our pipeline Vidya’s lead asset, VT-7208, an orally available, covalently binding, irreversible, central nervous system (“CNS”)-penetrant Bruton’s tyrosine kinase inhibitor (“BTKi”) rationally designed to optimize for selectivity, potency, and tolerability. In connection with the Vidya Acquisition, we received $200.0 million in gross proceeds from a concurrent private placement financing of shares of our non-voting convertible preferred stock (the “2026 Private Placement”). We intend to use the net proceeds of $187.1 million from the private placement to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept clinical trials of VT-7208 for food allergy, chronic spontaneous urticaria (“CSU”), and relapsing multiple sclerosis (“RMS”).
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Article 8 of Regulation S-X.
Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.
Liquidity
Our consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception. We have an accumulated deficit of $290.6 million at September 30, 2026. During the nine months ended September 30, 2026, we generated a net loss of $189.8 million and used $10.8 million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future.
On July 30, 2026, we closed the 2026 Private Placement, as described in Note 2, for gross proceeds of $200.0 million from which we received net proceeds of $187.1 million. At September 30, 2026, we had cash and cash equivalents totaling $180.2 million, which management believes will fund our planned operations for at least one year from the issuance date of these financial statements.
The Series A Preferred Stock are convertible into shares of common stock, subject to receiving stockholder approval of the issuance of shares of common stock upon conversion of Series A Preferred Stock and exercise of the Assumed Options (see Note 2 for additional information on the planned proposals for the stockholder meeting). Under the terms of the Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock (the “Certificate of Designation”), if we fail to deliver to the holder of the Series A Preferred Stock shares of our common stock underlying such shares of Series A Preferred Stock at any time nine months after the initial issuance of the Series A Preferred Stock, holders of the Series A Preferred Stock are entitled to require us to make cash payments by wire transfer of immediately available funds equal to the Fair Value (as defined in the Certificate of Designation) of such undelivered shares, subject to the applicable conversion-notice and delivery requirements, exceptions and availability of legally available funds. As a result, we concluded that the proceeds received from the private placement financing cannot be relied upon to mitigate the conditions that raised substantial doubt because the availability of those proceeds is subject to conditions that are not entirely within our control. Our plan to address this potential cash-settlement obligation is to obtain the requisite stockholder approval at a meeting expected to take place in the first quarter of 2027 and thereafter complete the conversion of the Series A Preferred Stock and delivery of the underlying common stock, subject to applicable beneficial ownership limitations. Accordingly, we concluded that substantial doubt about our ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.
Use of Estimates
In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.
Digital Assets
Our digital assets consist of Chiliz (CHZ) tokens and we have accounted for them in accordance with Accounting Standards Codification (“ASC”) 350-60, Intangibles – Goodwill and Other – Crypto Assets. We initially recorded the digital assets at cost and have subsequently remeasured at fair value as of the balance sheet date with changes in fair value recognized as unrealized gains or losses in the condensed consolidated statement of operations. During the nine months ended September 30, 2026, we sold 11 million for $0.2 million and recognized a realized loss of $0.2 million related to the sale. We will continue to recognize any realized gains or losses in the consolidated statement of operations based on the fair value of the digital assets on the date of sale or derecognition. We have now classified the digital assets as a current asset, as we expect to realize the tokens in cash within a year.
Income Taxes
We account for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At September 30, 2026 and December 31, 2025, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal.
Under ASC 740-270, Income Taxes – Interim Reporting, we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2026 and the foreseeable future since we expect to generate taxable net operating losses.
Concentration of Credit Risk
Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at September 30, 2026 exceeded FDIC limits.
Recent Accounting Pronouncements
In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU is intended to improve the disclosures related to expenses and provide investors more detailed information about certain types of expenses. This ASU is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on its consolidated financial statements and related disclosures.
|